Open access chemical and clinical probes to support drug discovery

被引：0
|
作者：
Aled M Edwards
Chas Bountra
David J Kerr
Timothy M Willson
机构：
[1] Aled M. Edwards is in the Structural Genomics Consortium,
[2] University of Toronto,undefined
[3] Toronto,undefined
[4] Ontario,undefined
[5] Canada.,undefined
[6] Chas Bountra is in the Structural Genomics Consortium,undefined
[7] University of Oxford,undefined
[8] Headington,undefined
[9] Oxford,undefined
[10] UK.,undefined
[11] David J. Kerr is at the Sidra Medical & Research Center,undefined
[12] Qatar Foundation,undefined
[13] Doha,undefined
[14] Qatar.,undefined
[15] Timothy M. Willson is in Discovery Medicinal Chemistry,undefined
[16] GlaxoSmithKline,undefined
[17] Research Triangle Park,undefined
[18] North Carolina,undefined
[19] USA.,undefined
来源：
Nature Chemical Biology | 2009年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Drug discovery resources in academia and industry are not used efficiently, to the detriment of industry and society. Duplication could be reduced, and productivity could be increased, by performing basic biology and clinical proofs of concept within open access industry-academia partnerships. Chemical biologists could play a central role in this effort.
引用
收藏
页码：436 / 440
页数：4
相关论文
共 50 条
  • [21] Donated chemical probes for open science
    Mueller, Susanne
    Ackloo, Suzanne
    Arrowsmith, Cheryl H.
    Bauser, Marcus
    Baryza, Jeremy L.
    Blagg, Julian
    Boettcher, Jark O.
    Bountra, Chas
    Brown, Peter J.
    Bunnage, Mark E.
    Carter, Adrian J.
    Damerell, David
    Doetsch, Volker
    Drewry, David H.
    Edwards, Aled M.
    Edwards, James
    Elkins, Jon M.
    Fischer, Christian
    Frye, Stephen V.
    Gollner, Andreas
    Grimshaw, Charles E.
    Ijzerman, Adriaan
    Hanke, Thomas
    Hartung, Ingo V.
    Hitchcock, Steve
    Howe, Trevor
    Hughes, Terry V.
    Laufer, Stefan
    Li, Volkhart M. J.
    Liras, Spiros
    Marsden, Brian D.
    Matsui, Hisanori
    Mathias, John
    O'Hagan, Ronan C.
    Owen, Dafydd R.
    Pande, Vineet
    Rauh, Daniel
    Rossenberg, Saul H.
    Roth, Bryan L.
    Schneider, Natalie S.
    Scholten, Cora
    Saikatendu, Kumar Singh
    Simeonov, Anton
    Takizawa, Masayuki
    Tse, Chris
    Thompson, Paul R.
    Treiber, Daniel K.
    Viana, Amelia Yi
    Wells, Carrow I.
    Willson, Timothy M.
    ELIFE, 2018, 7
  • [22] Open Innovation in Drug Discovery
    Ecker, Gerhard F.
    Williams-Jones, Bryn
    MOLECULAR INFORMATICS, 2012, 31 (08) : 519 - 520
  • [23] Wellcome support for open access
    Stephen Pincock
    Genome Biology, 4 (1)
  • [24] UK to support open access
    Banks, Michael
    PHYSICS WORLD, 2012, 25 (08) : 8 - 8
  • [25] Open Access, Education Research, and Discovery
    Furlough, Mike
    TEACHERS COLLEGE RECORD, 2010, 112 (10): : 2623 - 2648
  • [26] Open-access high-resolution mass spectrometry in early drug discovery
    Thomas, SR
    Gerhard, U
    JOURNAL OF MASS SPECTROMETRY, 2004, 39 (08): : 942 - 948
  • [27] Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
    Roy, Anuradha
    McDonald, Peter R.
    Sittampalam, Sitta
    Chaguturu, Rathnam
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2010, 11 (07) : 764 - 778
  • [28] Open Access Could Transform Drug Discovery: A Case Study of JQ1
    Arshad, Zeeshaan
    Smith, James
    Roberts, Mackenna
    Lee, Wen Hwa
    Davies, Ben
    Bure, Kim
    Hollander, Georg A.
    Dopson, Sue
    Bountra, Chas
    Brindley, David
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (03) : 321 - 332
  • [29] Fluorescent probes for proteolysis: Tools for drug discovery
    Neefjes, J
    Dantuma, NP
    NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) : 58 - 69
  • [30] Fluorescent probes for proteolysis: Tools for drug discovery
    Jacques Neefjes
    Nico P. Dantuma
    Nature Reviews Drug Discovery, 2004, 3 : 58 - 69
12345